Kling BioTherapeutics is a newly-formed Amsterdam UMC spin-off that is discovering and developing innovative antibody and antibody-derived drugs to treat cancer and infectious disease patients. With its lead program preparing to enter human clinical trials, Kling is well positioned to become an immuno-oncology biotech leader with a novel discovery platform and a robust pipeline of first in class oncology antibodies. Amsterdam UMC has partnered with U.S.-based venture capital firm Time BioVentures to build Kling, and is excited by the company’s rapid progress in attracting a world-class management team of seasoned drug development executives with impressive track records bringing breakthrough products to patients. The company’s offices and labs are located on Amsterdam UMC’s Meibergdreef campus.
For IXA -HvA and HvA Venture Centre 2024 started positive with their partnership in full swing. It is a milestone in the mission to support students from all AUAS faculties in developing their entrepreneurial competences. The Venture Centre is dedicated to nurturing the entrepreneurial spirit within AUAS student community. Through different initiatives like the 10K […]News
Berno Bucker will step into the role of interim director of Demonstrator Lab VU. He’s succeeding Linda van de Burgwal, who was director for the past two years. Berno is no stranger to the Demonstrator Lab, having launched his own start-up there six years ago and spending the last four years coaching Demonstrator Lab projects. […]News
To develop an optical spectroscopy device for sizing molecules and nanoparticlesNews